Related Experiment Videos
Cardiovascular risk of selective cyclooxygenase-2 inhibitors
Karsten Schrör1, Paulette Mehta, Jawahar L Mehta
1Department of Pharmacology and Clinical Pharmacology, University of Düsseldorf, Germany. kschroer@uni-duesseldorf.de
Abstract:
Recently, cyclooxygenase-2 (COX-2) inhibitors (coxibs), a class of drugs intended to be painkillers, have created unprecedented controversy because of their cardiovascular risk profile. The controversy has affected the patients, health-care providers, the Food and Drug Administration, and the manufacturers of these agents alike. We summarize the mechanisms of actions of this class of agents, their cardiovascular risk as evident in multiple trials, the basis of their adverse risk profile, and our views on this issue.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Coronary Artery Disease II: Pathophysiology